Haemonetics Learns the Hard Way
Executive Summary
After a failed excursion into the blood banking business, Haemonetics tries to get back on track by returning to its core business of manufacturing blood collection and blood salvage devices. Underestimating the perils of running blood collection centers, Haemonetics found itself diverting resources from its device business and alienating the customers with whom it now competed. A new management team is divesting the blood centers, refocusing on developing new products, and working to mend fences with former customers such as the Red Cross.You may also be interested in...
‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney
HBW Market News: GNC US Chief, Clasado Commercial Head, Barentz Funding
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
US Government Drug Pricing ‘Negotiation:’ Where We Go From Here
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.
Need a specific report? 1000+ reports available
Buy Reports